| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -8.2 | -11.6 |
| EPS (diluted, $ a share) | $-0.89 | $-5.93 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: PMN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
ProMIS Neurosciences Inc.: key numbers
- Share price
- $3.31Close, Nov 16
- Market cap
- $29.8M
- Shares outstanding
- 9MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from ProMIS Neurosciences Inc.
All →ProMIS Neurosciences Financial Results
ProMIS Neurosciences reported Q3 2026 financial results, ending the period with $44.1 million in cash which is expected to fund operations through 2027. The company reaffirmed that topline data from its Phase 1b PRECISE-AD trial of PMN310 in Alzheimer’s disease remains on track for the first quarter of 2027.
- Term
- Q3 2026
“The third quarter of 2026 has been productive for ProMIS, following encouraging interim data from our Phase 1b PRECISE-AD trial in Alzheimer’s disease (AD). Based on data generated to date, we continue to believe PMN310 offers a differentiated approach by selectively targeting the most toxic and destructive form of amyloid-beta, the oligomers.”
Neil Warma, President and Chief Executive Officer
“With PRECISE-AD closing out its final stage of patient visits, we look forward to reporting topline data in the first quarter of 2027, which will include safety, biomarker and clinical efficacy measures.”
Neil Warma, President and Chief Executive Officer
ProMIS Neurosciences Investor Presentation
ProMIS Neurosciences Inc. has posted an updated corporate presentation to its website and filed it as an exhibit to its 8-K. The presentation provides a strategic overview of the company's development pipeline, including its PMN310 candidate for Alzheimer's disease and the PRECISE-AD Phase 1b clinical trial. The filing serves as a Regulation FD disclosure to provide investors with current information on the company's operations and clinical milestones.
ProMIS Neurosciences Insider Eugene Williams Buys $90.9K of Stock
Eugene Williams bought 26,500 shares of ProMIS Neurosciences Inc. at $3.43 a share, worth $90.9K in total on Nov 4, 2026. Shares held after the trade: 40,213 (+193.2%).
- Value
- $90.9K
- Shares
- 26,500
- Price
- $3.43
- Holding change
- +193.2%
- Trade date
- Nov 4, 2026
ProMIS Neurosciences CSO Neil Cashman Buys $38.6K of Stock
Neil Cashman, CSO, bought 10,000 shares of ProMIS Neurosciences Inc. at $3.86 a share, worth $38.6K in total on Nov 2, 2026. Shares held after the trade: 14,532 (+220.7%).
- Value
- $38.6K
- Shares
- 10,000
- Price
- $3.86
- Role
- CSO
- Holding change
- +220.7%
- Trade date
- Nov 2, 2026